| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | Recombinant Elastase Proteins and Methods of Manufacturing and Use Thereof | US14715660 | 2015-05-19 | US20150329846A1 | 2015-11-19 | F. Nicholas Franano; Kimberly Bland; Marco D. Wong; Bee C. Ding |
| The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention. | ||||||
| 2 | Human pancreatic elastase | US602190 | 1990-10-22 | US5212068A | 1993-05-18 | Yo Takiguchi; Tokio Tani; Ichiro Kawashima; Jun Ohsumi; Hidehiko Furukawa; Toshinori Ohmine |
| Human pancreatic elastase can now be obtained from a genetically engineered source. | ||||||
| 3 | Preparation of elastase | US53824255 | 1955-10-03 | US2886489A | 1959-05-12 | GRANT NORMAN H; ROBBINS KENNETH C |
| 4 | Recombinant elastase proteins as well as processes for the preparation and use thereof | JP2010537075 | 2008-12-04 | JP2011505164A | 2011-02-24 | ディー． ウォン，マルコ; シー． ディン，ビー; フラナノ，エフ．ニコラス; ブランド，キンバリー |
| 本発明は、生物学的に活性な組換えエラスターゼタンパク質の製造、精製、製剤化、および使用のための方法に関する。 前記エラスターゼタンパク質を含む医薬組成物と同様に、治療的に有用なエラスターゼを作製する組換え法が説明される。 新規の組換えエラスターゼタンパク質およびタンパク質調製物もまた開示される。 本発明のエラスターゼタンパク質を含有する医薬組成物を用いて生体導管疾患を治療および予防する方法が説明される。 | ||||||
| 5 | 組換えエラスターゼタンパク質ならびにその製造方法および使用 | JP2015094887 | 2015-05-07 | JP6084653B2 | 2017-02-22 | フラナノ,エフ.ニコラス; ブランド,キンバリー; ウォン,マルコ ディー.; ディン,ビー シー. |
| 6 | 組換えエラスターゼタンパク質ならびにその製造方法および使用 | JP2010537075 | 2008-12-04 | JP5829808B2 | 2015-12-09 | フラナノ,エフ.ニコラス; ブランド,キンバリー; ウォン,マルコ ディー.; ディン,ビー シー. |
| 7 | Method for extraction of non-denaturated type-ii collagen having active epitope | JP2010204731 | 2010-09-13 | JP2012055292A | 2012-03-22 | MORIYAMA HIROYOSHI; SHIOJIMA YOSHIAKI; YOSHINARI ORIE |
| PROBLEM TO BE SOLVED: To provide a method for efficiently mass-extracting the epitope in a non-denaturated type-II collagen while keeping the epitope active, and to provide a food or drink using the resultant water-soluble non-denaturated type-II collagen subjected to the extraction by the method.SOLUTION: The method for extracting an active epitope in a water-soluble non-denaturated type-II collagen includes: a step of subjecting an animal-derived cartilage to a first extraction at 50°C or lower using an acidic solution; and a step of adding pepsin to the resultant acidic solution followed by subjecting the resultant cartilage to a second extraction at 40°C or lower. | ||||||
| 8 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | EP16721510.2 | 2016-04-07 | EP3280401A1 | 2018-02-14 | Nathan, Ilana; Khalfin, Boris |
| Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well. | ||||||
| 9 | Recombinant elastase proteins and methods of manufacturing and use thereof | EP13181046.7 | 2008-12-04 | EP2666854A1 | 2013-11-27 | Franano, Nicholas F.; Bland, Kimberly; Wong, Marco D.; Ding, Bee C. |
Methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention. |
||||||
| 10 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | US15564836 | 2016-04-07 | US20180312477A1 | 2018-11-01 | Ilana Nathan; Boris Khalfin |
| Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well. | ||||||
| 11 | RECOMBINANT ELASTASE PROTEINS AND METHODS OF MANUFACTURING AND USE THEREOF | US15880029 | 2018-01-25 | US20180155703A1 | 2018-06-07 | F. Nicholas FRANANO; Kimberly Bland; Marco D. Wong; Bee C. Ding |
| The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention. | ||||||
| 12 | METHOD FOR EXTRACTING UNDENATURED TYPE II COLLAGEN HAVING ACTIVE EPITOPE | US13812280 | 2011-07-14 | US20130123468A1 | 2013-05-16 | Hiroyoshi Moriyama; Orie Yoshinari; Yoshiaki Shiojima |
| A method for extracting water-soluble undenatured type II collagen having an active epitope comprises a first step for extracting animal-derived cartilage using an acidic solution at 50° C. or less, and a second step for adding pepsin to the acidic solution and performing extraction at 40° C. or less. This allows the epitope of undenatured type II collagen to be extracted in large quantities and with high efficiency without any loss of activity, and makes it possible to provide a food or beverage product obtained using the water-soluble undenatured type II collagen extracted by the extraction method. | ||||||
| 13 | Pro-elastase and preparation thereof | US53824155 | 1955-10-03 | US2893920A | 1959-07-07 | GRANT NORMAN H; ROBBINS KENNETH C |
| 14 | RECOMBINANT ELASTASE PROTEINS AND METHODS OF MANUFACTURING AND USE THEREOF | US15726607 | 2017-10-06 | US20180273928A1 | 2018-09-27 | F. Nicholas FRANANO; Kimberly S. Bland; Marco D. Wong; Bee C. Ding |
| The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention. | ||||||
| 15 | NUCLEIC ACID MOLECULES ENCODING AUTOACTIVATING TYPE I PANCREATIC PROELASTASE PROTEINS | US15919814 | 2018-03-13 | US20180208918A1 | 2018-07-26 | F. Nicholas Franano; Kimberly Bland; Marco D. Wong; Bee C. Ding |
| The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention. | ||||||
| 16 | RECOMBINANT ELASTASE PROTEINS AND METHODS OF MANUFACTURING AND USE THEREOF | US14957765 | 2015-12-03 | US20160243205A1 | 2016-08-25 | F. Nicholas FRANANO; Kimberly S. Bland; Marco D. Wong; Bee C. Ding |
| The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention. | ||||||
| 17 | RECOMBINANT ELASTASE PROTEINS AND METHODS OF MANUFACTURING AND USE THEREOF | US13957954 | 2013-08-02 | US20130336956A1 | 2013-12-19 | F. Nicholas Franano; Kimberly S. Bland; Marco D. Wong; Bee C. Ding |
| The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention. | ||||||
| 18 | カテプシンCおよび/またはCELA1および/またはCELA3Aおよび/またはそれらに構造的に関連する酵素を特異的に標的とする細胞および/または組織壊死の処置および/または防止のための組成物 | JP2018503839 | 2016-04-07 | JP2018515597A | 2018-06-14 | イラーナ ネイサン; ボリス ハルフィン |
| カテプシンC、CELA1、CELA3Aおよび/またはそれらに構造的に関連する分子のインヒビター化合物および薬剤、それらを含む組成物、および細胞および/または組織壊死の抑制および/または防止におけるそれらの使用が記載される。記載された化合物についての様々な適用、および併用療法も同様に説明される。 | ||||||
| 19 | 組換えエラスターゼタンパク質ならびにその製造方法および使用 | JP2017011160 | 2017-01-25 | JP2017104114A | 2017-06-15 | フラナノ,エフ.ニコラス; ブランド,キンバリー; ウォン,マルコ ディー.; ディン,ビー シー. |
| 【課題】生物学的に活性な組換えエラスターゼタンパク質の製造、精製、製剤化、および使用のための方法。 【解決手段】エラスターゼタンパク質を含む医薬組成物と同様に治療的に有用なエラスターゼを作製する組換え法。新規の組換えエラスターゼタンパク質およびタンパク質調製物。エラスターゼタンパク質を含有する医薬組成物を用いて生体導管疾患を治療および予防する方法。 【選択図】なし |
||||||
| 20 | 組換えエラスターゼタンパク質ならびにその製造方法および使用 | JP2015094887 | 2015-05-07 | JP2015172056A | 2015-10-01 | フラナノ,エフ.ニコラス; ブランド,キンバリー; ウォン,マルコ ディー.; ディン,ビー シー. |
| 【課題】エラスターゼ治療において望ましくない作用(例、プロテアーゼ活性化受容体1及び2活性化等)をもたらすトリプシンを含有しない、高純度組換えエラスターゼタンパク質含有医薬組成物の提供。 【解決手段】特定のアミノ酸配列と少なくとも95%の配列同一性を有するアミノ酸配列を含む成熟ヒトI型エラスターゼタンパク質を含む医薬組成物。前記組成物におけるトリプシン含有量は4ng未満であることが好ましい。前記組成物は、動脈又は静脈等の生体導管疾患用いることができる。 【選択図】なし |
||||||
QQ群二维码
意见反馈
意见反馈